Overall survival of patients who received bevacizumab after progression compared to those who didn’t.

Patients receiving bevacizumab had a median OS of 23.3 months (95% CI: 17.1–35.6), compared to 16.3 months (95% CI: 13.8–25.1) in patients who did not receive it, P = 0.0284.